US EditionNovo Nordisk partners with Ro, Hims and LifeMD to sell low-cost Wegovy
- Novo Nordisk announced on May 2, 2025, that it will sell branded Wegovy through telehealth companies Hims & Hers, Ro, and LifeMD in the US via its NovoCare Pharmacy.
- This follows a federal court rejecting compounding pharmacies' challenge to FDA's end of Wegovy shortage, which had allowed unauthorized copies during supply constraints.
- The deals enable consumers without insurance to purchase Wegovy at $499 per month, with Hims charging $599, and include telehealth services like clinical support and nutrition guidance.
- Novo Nordisk’s obesity drug currently generates $8.4 billion in sales but faces competition from Eli Lilly's Zepbound, which shows stronger weight loss results and similar telehealth partnerships.
- The partnerships aim to expand affordable Wegovy access as compounding pharmacies stop copycat production, while Novo Nordisk’s and partners' shares rose following the announcement.
31 Articles
31 Articles
Novo Nordisk, the owner of Ozempic, wants to revive his dream on the Stock Exchange with new alliances
European pharmaceutical giant Novo Nordisk seeks to regain investors’ interest again, and put an end to his punishment on the Stock Exchange, resulting from doubts about his future treatments. The Nordic group that jumped to fame by Ozempic has announced this week a new trade agreement, now with the Hims & Hers Health group, for the sale of its popular weight loss medication Wegovy through several telemedicine platforms at a very low price.
Tired of the runaround? Hims makes ED treatment simple, private, and affordable
Taking care of your health is a power move, and not something we say enough. This includes addressing issues like erectile dysfunction. If you’re dragging your feet because getting treatment seems like a hassle or embarrassing, consider this your wake-up call! Hims has made ED treatment accessible, private, and believe it or not, affordable. Options […] The post Tired of the runaround? Hims makes ED treatment simple, private, and affordable appe…
Wegovy-Maker Novo Teams with Online Pharmacies as Lilly Rivalry Heats Up
All it takes to change a pest to a partner is a signature on a dotted line. Danish pharmaceutical giant Novo Nordisk, the maker of leading weight-loss drug Wegovy, is signing a deal with online telehealth storefronts that ate a chunk of its business selling cheap knockoffs during shortages last year. Slimmed-Down Offering Novo Nordisk’s strategic partnerships with telehealth providers represent an aggressive bid to secure market dominance agains…
Novo Nordisk to sell Wegovy through telehealth firms to cash-paying US customers
Novo Nordisk said on Tuesday it was working with telehealth firms Hims & Hers , Ro and LifeMD to sell Wegovy, as it looks to stem sales of copies of its popular weight-loss drug and expand access to cash-paying patients.
Novo Nordisk partners with Ro, Hims and LifeMD to sell low-cost Wegovy
Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular weight-loss drug Wegovy. The pharmaceutical company announced it would be partnering with Hims & Hers., LifeMD and Ro. to provide all five dose strengths of its weight-loss GLP-1 medication Wegovy at a reduced cost of $499. All doses will be delivered with a once-weekly single-dose pen. Novo Nordisk's direct-to-consumer pha…
Coverage Details
Bias Distribution
- 77% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
